Therapeutic strategies targeting these core mechanisms—from SGLT2 inhibitors and GLP-1 RAs to MRAs—have demonstrated meaningful benefits in slowing atherosclerosis progression and mitigating cardiovascular risks. This evidence concerns the gene GLP1R and atherosclerosis.